CD8A and prostate carcinoma: Contrastingly, a prostate cancer trial of neoadjuvant SBRT before radical prostatectomy conducted in only six patients revealed that immune environment was altered 2 weeks after SBRT, with a reduction in CD8+ T cells and an increase in CD68 and CD163 macrophages [18].